

0410

#4


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Stoll, et al

Examiner: Unknown

Serial No: 10/002,643

Art Unit: Unknown



For: DEVICE FOR INFLUENCING CELL-GROWTH MECHANISMS IN
VESSELS OF A HUMAN OR ANIMAL BODY

Filed: 31 OCTOBER 2001

Date: 29 May 2002

Commissioner of Patents and Trademarks
Washington, D.C. 20231

TRANSMITTAL

Transmitted herewith:

- 1) Supplemental Information Disclosure Statement Under 37 CFR § 1.97;
- 2) Copies of four (4) Patent References, four (4) non patent documents; and
- 3) Acknowledgment of Receipt/Return Card

Respectfully submitted,

HAHN LOESER + PARKS LLP

Stephen L. Grant
Registration 33,390

Twin Oaks Estate
1225 West Market Street
Akron, OH 44313-7188
(330) 864-5550

Our File: 117163-31


CERTIFICATE OF MAILING (37 CFR 1.10)

I hereby certify that this paper is being deposited with the United States Postal Service in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231.

29 MAY 2002

Date

Stephen L. Grant



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Stoll, et al.

Examiner:

Serial No: 10/002,643

Art Unit:

For: DEVICE FOR INFLUENCING CELL-GROWTH MECHANISMS IN
VESSELS OF A HUMAN OR ANIMAL BODY

Filed: 31 October 2001

Date: 28 May 2002

Commissioner of Patents and Trademarks
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Under 37 CFR 1.97

This Supplemental Information Disclosure Statement is filed more than three months after the filing date of the patent application, but it is filed before an Office Action on the merits and is filed within three months after the receipt of a search report from a foreign Patent Office, so it is timely filed without payment of a fee. 37 CFR §1.97(b)(3) and (c)(1).

The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 CFR §1.56(g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13, at 25.

This Information Disclosure Statement is made to comply with the duty of candor imposed on all individuals associated with the filing or prosecution of this application, as defined by 37 CFR §1.56(c).

One (1) U.S. patent and three (3) foreign patent documents are listed on the attached one (1) sheet of Form PTO/SB/08A which is made a part hereof. A copy of each is enclosed. Four (4) non-patent documents are reported on the attached two (2) sheets of Form PTO/SB/08B, which is made a part hereof. Also enclosed, but not listed on the Form PTO/SB/08A, is a copy of the search report from the European Patent Office, dated 22 May 2002, in case EP 01 25 0365, which is based upon the same priority application (DE 100 55 686.8) as the present case. There are no overlapping references with the German search report, which was reported in the Information disclosure Statement filed with the filing papers.

All references are in English except Reference FD, which is in German, but which is provided with an English language abstract on the second page thereof.

The foregoing Information Disclosure Statement is based upon the information known to the inventor or contained in the undersigned attorney's file as of the filing date of this statement and is inclusive of the best information known to each of the undersigned at that date. Prompt consideration of the Information Disclosure Statement and the references by the Examiner is earnestly requested.

Respectfully submitted,



Stephen L. Grant
Reg. No. 33,390


Hahn Loeser & Parks LLP
1225 West Market Street
Akron, Ohio 44313
330/864-5550
Atty. Docket: 117163-31



Information Disclosure Statement by Applicant (PTO/SB/08B);
Additional Other Prior Art - Non Patent Literature Documents

Attachment 1

- a. FA
- b. SONTAG, ET AL, "Response to Cytosolic calcium, Cyclic AMP and Cyclic GMP in dimethylsulfoxide-differentiated HL-60 cells to modulated low frequency electric currents," Bioelectromechanics, Wiley-Liss, Inc., p. 452-56, (May 28, 1998).
- c.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet <u>1</u> of <u>1</u>			Complete if Known	
			Application Number	10/002.643
			Filing Date	10/31/2001
			First Named Inventor	Dr. Hans-Peter Stoll
			Art Unit	
			Examiner Name	
			Attorney Docket Number	117163-32

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	DA	US- 5078736	01/07/1992	Behl	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			


FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
		Country Code3	-Number4	-Kind Code5 (if known)				
	EA	WO	00/13585	A1	03/16/2000	Sormann		
	EB	EP	1 036 574	A1	09/20/2000	Diamantopoulos		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/002.643
		Filing Date	10/31/2001
		First Named Inventor	Dr. Hans-Peter Stoll
		Group Art Unit	
		Examiner Name	
Sheet 1 of 1	Attorney Docket Number	117163-32	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	See Attached		
	FB	INDOLFI, ET AL., "Mechanisms of restenosis afetr angioplasty and approach to therapy," Intl J. of Molecular Med., p. 143-48, (May 28, 1998).	
	FC	NINDL, ET AL., "Experiments showing that electromagnetic fields can be used to treat inflammatory diseases," Biomedical Sciences Instrumentation, p. 7-13, (April 28, 2000).	
	FD	BETZ, E., "Migration and Proliferation of Vascular Smooth Muscle Cells," Drug Research, Vol. 40 (No. 3a), p. 362-65, (May 28, 1990).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

